This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
The German drugmaker confirmed acquisition talks, but cautioned a deal may not m...
Oxford Cannabinoid Technologies is shedding its old skin. Having delisted its st...
Herbal medicinal product: Boldi foliumArray, C: ongoing call for scientific data
Early diagnosis and treatment of ADHD could help prevent young people from picki...
Human medicines European public assessment report (EPAR): CoAprovel, irbesartan,...
Human medicines European public assessment report (EPAR): Karvezide, irbesartan,...
Voyager Therapeutics no longer expects to take its amyotrophic lateral sclerosis...
Human medicines European public assessment report (EPAR): Repaglinide Teva, repa...
Merck KGaA is in advanced talks to acquire cancer and rare disease specialist Sp...
Webinar on PMS Project Made Easy: Summary of activities and Practical Tips for S...
As always, if you know of layoffs occurring at a biotech, please reach out to th...
Human medicines European public assessment report (EPAR): Aprovel, irbesartan, D...
Executive Steering Group on Shortages and Safety of Medicinal Products
In the latest edition of STAT's Health Tech newsletter: Biotech companies and hy...
Ebola cases in Uganda have risen to nine, while 265 other people were being moni...
Human medicines European public assessment report (EPAR): Ultibro Breezhaler, in...
The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and ret...
Human medicines European public assessment report (EPAR): Armisarte (previously ...
Human medicines European public assessment report (EPAR): Pluvicto, lutetium (17...
New Hampshire’s Bio X Cell, which has made a name for itself over the past quart...
Older millennials, take note: Bayer is worried about your heart health. The drug...
Artificial intelligence could be used to prescribe medications to patients — if ...